Advertisement

Comparison of Propranolol and Atenolol in the Control of Hyperparathyroidism in Uremia

  • R. Makdassi
  • M. Andrejak
  • Ph. Morinière
  • J. L. Sebert
  • S. Decourt
  • J. Guéris
  • B. Coevoet
  • A. Fournier
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 151)

Abstract

Secondary hyperparathyroidism is a constant and not yet resolved complication of chronic renal failure. Current therapeutic methods for parathyroid gland suppression in uremic patients are mainly based on the use of phosphate binders, oral calcium supplementation and eventually on administration of vitamin D metabolites (1). Since these measures are not always quite successful, it is interesting to evaluate other measures suggested by recent physiological data on the regulation of PTH secretion. As a matter of fact, beside the circulating levels of ionized calcium and magnesium (2), PTH secretion appears to be regulated by substances such as dopamine, histamine (via H2 receptors), secretine, glucagon, PgE2 and catecholamines (3).

Keywords

Secondary Hyperparathyroidism Uremic Patient Parathyroid Hormone Secretion Propranolol Group Chronic Oral Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1-.
    A. Fournier, Ph. Morinière, B. Coevoet, R. Makdassi A. Roussel, P.H. Decourcelle, J. Kassouf, G. Lambrey J.F. de Fremont, J.L. Sebert. “Prevention and medical treatment of secondary hyperparathyroidism of chronic renal failure in the adult in “Advances in Nephrology from the Necker Hospital” ed. by Grunfeld J.P., M.H. Maxwell Year Book Medical Publisher Chicago 1981 (in print).Google Scholar
  2. 2-.
    J.H. Targovnik, J.S. Rodman, L.M. Sherwood. “Regulation of parathyroid hormone secretion in vitro:quantitative aspects of calcium and magnesium on control”. Endocrinology, 88: 1477–1482 (1971).PubMedCrossRefGoogle Scholar
  3. 3-.
    E.M. Brown, D.G. Gardner, R.A. Windeck, S. Hurwitz, M.F. Brennan, G.D. Aurbach. “B adrenergically stimulated 3,5-monophosphate accumulation in and parathyroid hormone release from dispersed human parathyroid cells”. J. Clin. Endocrinol. Metab. 48:618–626 (1979)PubMedCrossRefGoogle Scholar
  4. 4-.
    G.D. Aurbach, E.M. Brown, S.J. Marx, “Receptors and cyclic nucleotides in secretion of parathyroid hormone”. Calcif. Tiss. Res. Supp 22:117–126 (1977).CrossRefGoogle Scholar
  5. 5-.
    G.A. Williams, G.K. Hargis, E.M. Bowser, W.J. Henderson, N.J. Martinez, “Evidence for a role of adenosine 3′5′ monophosphate in parathyroid hormonerelease”. Endocrinology, 92: 687–691 (1973).PubMedCrossRefGoogle Scholar
  6. 6-.
    J.A. Fischer, J.W. Blum. “Non calcium control of parathyroid hormone secretion” Mineral Electrolyte Metab. 1: 158–166 (1980).Google Scholar
  7. 7-.
    S.C. Kukreja, G.K. Hargis, E.N. Bowser, W.J. Henderson, E.W. Fisherman, G.A. Williams. “Role of adrenergic stimuli in parathyroid hormone secretion in man. J. Clin. Endocrinol. Metab. 40: 478–481 (1975).PubMedCrossRefGoogle Scholar
  8. 8-.
    M.S. Christensen, O. Brandsborg, N.J. Christensen. Inhibition of parathyroid hormone secretion by isoproterenol. In “Phosphate metabolism”ed. by Massry E.Ritz, Plenum Press, New York, London:363–368 (1977)Google Scholar
  9. 9-.
    J.F. Caro, A. Besarab, J.F. Burke, J.A. Glennon. “A possible role for propranolol in the treatment of renal osteodystrophy”. Lancet, ii: 451–453(1978)CrossRefGoogle Scholar
  10. 10-.
    D. Brancaccio, C. Gacnozzi, S. Casati, D. Rurale, S. Belloli, A. Aroldi, G. Graziani, C. Ponticelli. “Propranolol and uremic osteodystrophy”. EDTA Proceeding, Abstract 12 (1979).Google Scholar
  11. 11-.
    M. Surian, G. Colussi, G. Civati, S. Masi, B. Corradi, F. Malberti, H. Barbiano, G. di Belgiojoso, L. Minetti “No effect of chronic propranolol therapy in lowering plasma parathyroid hormone and in reducing osteodystrophy incidence in hemodialysis patients”. EDTA Congress, Abstract 95 (1980).Google Scholar
  12. 12-.
    K. Farrington, J. Hamzeh, Z. Varghese, J.F. Moorhead “Effect of oral propranolol on parathyroid hormone secretion in chronic renal failure”. Brit. Med. J. 281: 1320 (1978).Google Scholar
  13. 13-.
    A. Bessarab, J.F. Carro, B.V. Ihle, J.F. Burke, J.A. Glennon, J.A. Fischer. “Suppression of secondary hyperparathyroidism by propranolol in renal failure patients”. Nephron, 27: 127–133 (1981).CrossRefGoogle Scholar
  14. 14-.
    B. Coevoet, C. Desplan, J.L. Sebert, R. Makdassi, M. Andrejak, J.D. Gheerbrant, M. Tolani, C. Calmette, M.S. Moukthar, A. Fournier. “Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretion in uremic patients”. Brit. Med. J. 280: 1344–1346 (1980).PubMedCrossRefGoogle Scholar
  15. 15-.
    J. Guéris, C. Ferrière. “Hétérogénéité de la parathormone plasmatique chez l’homme”, Path. Biol. 23: 821–826 (1975).Google Scholar
  16. 16-.
    G. Desplan, A. Jullienne, M.S. Moukthar, G. Milhaud “Sensitive assay for biologically active fragment of human parathyroid hormon”. Lancet ii: 198–199 (1977)Google Scholar
  17. 17-.
    J.L. Sebert, A. Fournier, J. Guéris, G. Lambrey, J.F. de Fremont, P. Marié, R. Makdassi, A. Smadja, A. Marié, D. Kuntz, A. Ryckewaert, J. Quichaud, P. Meunier. “Limit by phosphatemia of the usefulness of vitamin D metabolites (1 hydroxycholecalciferol and 25 hydroxycholecalciferol) in the treatment of renal osteodystrophy.” Metab. Bone Dis. and Rel. Res. 2: 217–222 (1980).CrossRefGoogle Scholar
  18. 18-.
    J.L. Vigo, E.E. Polli, G. Milhaud, M.S. Moukthar, C. Desplan, J. Duriez. “Amino terminal parathyroid hormoneradio-immunoassay to evaluate bone status in renal failure”. Lancet, i,: 443–444 (1981).Google Scholar
  19. 19-.
    M.S. Moukthar, A. Jullienne, P. Rivaille, G.Milhaud “Dosage radio-immunologique de la calcitonine humaine”. In Radio-immunoassay and Related Procedures in Medicine. Vienne: International Atomic Energy Agency, 379–397 (1974).Google Scholar
  20. 20-.
    M.A. Preece, J.L.M. O’Riordan, M. Lawsonde, K. Kodicek “A competitive protein binding assay for 25 hydroxy cholecalciferol and 25 hydroxyergocalciferol”. Clin. Chem. Act. 54: 235–242 (1974).CrossRefGoogle Scholar
  21. 21-.
    S. Decourt, B. Flouvat. “Dosage dans les milieux biologiques d’un nouveau bétabloquant l’1tenolol par Chromatographie liquide à haute performance”. J. Chromatography. 174: 258–263 (1979).CrossRefGoogle Scholar
  22. 22-.
    C.K. Grumb, M. Martinez Maldonado, Garabede, W.N. Suki. “Effects of volume expansion, purified parathyroid extract and calcium on renal bicarbonate reabsorption in the dog”. J. Invest. 54: 1287–1290 (1974).CrossRefGoogle Scholar
  23. 23-.
    E.M. Brown, S. Hurwitz, G.D. Aurbach. “Beta-adrenergic stimulation of cyclic AMP content and parathyroid hormone release from isolated bovine parathyroid cells”. Endocrinology 100: 1696–1702 (1977).PubMedCrossRefGoogle Scholar
  24. 24-.
    G. Leonetti, G. Mayer, A. Morganti, L. Terzauli, A. Zanchetti, C.A. Chidsey. “Hypotensive and renin suppressing activities of propranolol in hypertensive patients. Clin. Sci. Mol. Med. 48, 491–499 (1975).Google Scholar
  25. 25-.
    A. Amery, J.F. de Plaen, P. Lijnen, J. Mc Ainsh, T. Reybrouck. “Relationship between blood level of atenolol and pharmacologic effect”. Clin. Pharmacol. Therap. 21, 691–699 (1977).Google Scholar
  26. 26-.
    A. Kaneto, E. Miki, K. Kosaka. “Effect of B1 and B2 adrenoreceptor stimulant infused intrapancreatically on glucagon and insulin secretion”. Endocrinology 97: 1166–1173 (1975).PubMedCrossRefGoogle Scholar
  27. 27-.
    A. Luyck. “Le rôle du glucagon dans l’hyperglycémië Diabète et Métabolisme i: 201–208 (1975).Google Scholar
  28. 28-.
    J. Freitag, K.J. Martin, K.A. Hruska, C. Anderson, M. Conrades, E. Slatopolsky”. Impaired parathyroid hormone metabolism in patients with chronic renal failure”. New England J. Med. 208: 29–32 (1978).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • R. Makdassi
    • 1
    • 4
  • M. Andrejak
    • 1
    • 4
  • Ph. Morinière
    • 1
    • 4
  • J. L. Sebert
    • 1
    • 4
  • S. Decourt
    • 2
    • 4
  • J. Guéris
    • 3
    • 4
  • B. Coevoet
    • 1
    • 4
  • A. Fournier
    • 1
    • 4
  1. 1.CHU AmiensParisFrance
  2. 2.Hop.A.ParéParisFrance
  3. 3.Hop.LariboisièreParisFrance
  4. 4.Service de NéphrologieHôpital NordAmiensFrance

Personalised recommendations